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ABSTRACT
Defining the Properties of the OS-33 Osteosarcoma Cell Line and Effects of mTORC1
Inhibition by Rapamycin
Mykayla Palmer
Director: Dr. Jianning Tao, PhD
Osteosarcoma (OS) is the predominant form of primary malignant bone cancer
and is most commonly found in children and adolescents. OS is associated with high
mortality rates and poor prognosis for the majority of patients [1]. Within the last few
decades, there has been little to no improvement in patient outcome. Current treatment
methods include surgical excision of the tumor alongside chemotherapy. However, high
rates of metastasis still persist, which is considerably more difficult to target with
chemotherapy or to remove by surgery [2].
Thanks to recent advances in molecular genetics and medicine, we can better
understand OS and the properties of the cancer in order to develop an improved treatment
plan. We examined a novel Patient Derived Xenograft (PDX) cell line, OS-33. While
little is known about OS-33, preliminary data indicates sensitivity to the drug rapamycin,
which is suggested to inhibit the mammalian target of rapamycin complex 1 (mTORC1)
pathway [3]. The mTORC1 pathway is upregulated in many OS patients, which
highlights this pathway as a new and promising therapeutic target [3]. The inhibition of
mTORC1 signaling by rapamycin was studied to determine how it suppresses cell

migration, invasion, proliferation, and stem cell differentiation in the OS-33 cell line.
This study underlines the importance of the mTORC1 signaling pathway and provides
evidence for potential drugs which target OS.
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CHAPTER ONE
Introduction
Defining the Properties of the OS-33 Osteosarcoma Cell Line and Effects of
mTORC1 Inhibition by Rapamycin
Osteosarcoma (OS) is a primary malignant bone cancer caused by the aberrant
proliferation of immature bone tissue [4]. Often, the tumor is found in long bone tissues,
specifically in the tibia, humerus, and femur [5]. 3.1 cases per million of OS occur each
year and generally affect children with immature osteoid tissues [6]. OS is a rare, but
aggressive cancer. According to previous literature, the survival rate after 5 years is as
low as 61.6% [7].
Historical treatment methods for OS focuses on local therapy, such as surgical
excision of the bone tumor; however, OS is known to have high rates of tumor
metastasis, which is difficult to control or prevent. Nearly 30% of patients who receive
surgical excision treatment were diagnosed with a metastatic tumor [8]. Most commonly,
tumor metastasis occurs in the lungs [8]. New clinical trials show that a combination of
drug therapy and chemotherapy will increase patient survival rates [9]. By using
combined methods, there was a higher success rate for removal the primary tumor and
preventing metastasis [2]. However, better regimens and new drugs are required for the
group of patients with metastatic osteosarcoma at diagnosis.
In order to implement combination therapies, it is essential to understand the
molecular mechanisms behind which OS operates. The mTORC1 pathway is a kinase
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cascade pathway which has been found to have sporadic gene mutations in OS, called
genetic drivers [10]. These drivers are found in 24% of OS patients and allow for
targeting of the kinases with an mTORC1 inhibitor, such as rapamycin [10, 11]. It is
imperative to understand how rapamycin and other treatments inhibit the mTORC1
pathway in order to target osteosarcoma tumors and metastasis. Doxorubicin, which is a
common chemotherapy drug used in current treatment methods, was tested in conjunction
with rapamycin as a combination therapy treatment [12]. Due to high levels of
doxorubicin toxicity, only small doses may be used when treating OS patients [12]. This
presents the need for other drugs to be used in conjunction with doxorubicin in order to
limit toxicity. By adding rapamycin to doxorubicin, the possibility for a more efficient
and safer treatment method can be assessed.
This study focuses on the inhibition of mTORC1 signaling by rapamycin to
determine if inhibitor suppresses cell migration, invasion, proliferation, and stem cell
differentiation. Specifically, the experiments explored the OS-33 cell line, which is a
novel line derived from a human PDX. The purpose of this study is to better understand
the characteristics of OS-33. After obtaining preliminary results, synergistic combination
therapy treatments with doxorubicin were implemented to better target osteosarcoma and
metastases.
The properties of OS-33 were defined by using a series of in vitro experiments
involving treatment of the OS-33 cell line with or without rapamycin at various
concentrations (0, 0.1, 1, 10 ng/mL, etc.). These experiments included, but were not
limited to: Western blot analysis, scratch assay, proliferation assay, trans-well
migration/invasion assay, adipocyte differentiation, and osteoblast differentiation. Our
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study suggests that OS-33 cell growth is inhibited by rapamycin treatment and that
combination therapies downregulate mTORC1 expression. Our results as a whole help us
to define the properties of the OS-33 cell line and to better understand OS. This study
also underlines the importance of targeting osteosarcoma with combination therapy in
order to decrease metastatic rates and improve patient prognosis.
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CHAPTER TWO
Materials and Methods

OS-33 Cell Line
The OS-33 OS samples were derived from a Patient Derived Xenograft (PDX) tumor
obtained from Dr. Peter Houghton at University of Texas Health Sciences in San
Antonio, TX. The tissue sample was originally generated from a human OS tissue sample
and used to develop into a novel cell line in Dr. Jianning Tao’s lab. OS-33 was cultured
in MEM Alpha Modification (1X) Medium (with L-Glutamine, Ribonucleosides,
Deoxyribonucleosides) plus 10% Fetal Bovine Serum and 1% Penicillin-Streptomycin.
Medium was obtained through GE Healthcare Life Sciences HyClone laboratories. OS33 cells were stored in incubation units at 37°C with 5% CO2 release and medium
changes were conducted every 3-4 days. Unless stated otherwise, cells were incubated in
this manner for both experiments and culturing. Cell lines were grown in 100 mm Fisher
Scientific tissue culture dishes. Once grown to complete confluency, cells were passaged
by rinsing with Phosphate-Buffered Saline (PBS, 0.01 mol/L, pH 7.4), adding 0.25%
Trypsin-EDTA (1X) for 3-5 minutes in order to dissociate cells from the bottom of the
plate, and then splitting cells into different plates.
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C2C12 and L2 Control Cell Lines
The L2 and C2C12 mouse cell lines were used as control cell lines in experiments. All
cell lines listed were cultured in MEM Alpha Modification (1X) Medium plus 10% Fetal
Bovine Serum, and 1% Penicillin Streptomycin as described previously. Unless otherwise
stated, cell lines were cultured in this manner and incubated at 37°C with 5% CO2
release. Medium changes were conducted as necessary.

Rapamycin Storage, Preparation, and Treatment
The rapamycin stock was stored in a -80°C freezer. The
drug was dissolved in 100% ethanol to make 10 mg/mL and further diluted to several
varying µg/mL stock solutions for usage in experiments. In control groups, the ethanol
served as the vehicle and a corresponding amount was added. These were stored in a 20°C freezer and used for treating cells with a 1:1000 dilution into medium. The dosage
and timeframe of rapamycin treatment in our experiments was described in the result
section to define how treatment affects the OS-33 cell line migration, proliferation, and
translation.

Karyotype Analysis
OS-33 cells were frozen and sent for karyotype analysis, which was conducted by Dr.
Patricia Crotwell-Leiferman and Alan Ross in core of Sanford Imagenetics of Sanford
Health in Sioux Falls, S.D.
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Western Blot Analysis
Four 100 mm plates of OS-33 cells were grown for 24 hours with 0, 0.1, 1, and 10 ng/mL
rapamycin treatment. After 24 hours, the treated OS-33 plates were rinsed with PBS.
Then, cells were lysed with a lysis buffer consisting of 750 µL SDS, 675 µL PBS, and 75
µL DTT. Immediately after addition of the buffer, plates were “scraped” with a Fisher
Scientific cell scraper to collect the proteins. Using a pipette, the contents of the plate
were retrieved and stored in a labeled 1.5 mL Microcentrifuge Tube. This process was
repeated for all treated OS-33 plates, ensuring not to cross contaminate. Vials containing
the OS-33 cell lysates were immediately heated at 95°C for 5 minutes before being frozen
in a -20°C freezer until needed for Western blot analysis.
Once ready for analysis, the rapamycin-treated OS-33 protein lysates were removed from
the freezer and heated at 95°C for 5 minutes. Lysates were then sonicated and returned to
the 95°C heater. Using a gel electrophoresis instrument and protein lysates with 4–20%
Mini-PROTEAN® TGX™ Precast Protein Gels, the previously collected OS-33 proteins
were loaded with a pipette tip and electrophoresis was conducted at 200 V for 45
minutes. A dual color ladder was used for indication of sizes and locations of proteins in
the gel. After running the gel, the membrane was placed in methanol solution and 1X
Transfer Buffer. A PVDF membrane was loaded into a semi-dry Bio-Rad Trans-blot
apparatus and protein samples were transferred. The membrane was then probed with
mouse anti-Vinculin antibody, S6 antibody, and pS6 antibody. A secondary antibody was
added for one hour. The secondary antibody was anti-rabbit for the anti-Vinculin
antibody and anti-mouse for the pS6 and s6 antibodies. Membranes were treated with 0.5
mL Luminal/Enhancer Solution and 0.5 mL Super Signal West Pico Stable Peroxide
6

Solution before imaging on a UVP imager. Density and relative expression level were
calculated and compared using NIH Image J.

Colony Formation Assay
OS-33 cells were counted using trypan blue and a Countess cell counter. Using full
medium treated with 0.1 ng/mL rapamycin, 1 ng/mL rapamycin, or 100% ethanol (0
ng/mL rapamycin), cells were diluted to 1,000 cells/mL and seeded into a 6-well Fisher
Scientific tissue culture plate. Then, OS-33 cells were monitored over several days for
colony formation. After a 16-day period, cells were rinsed with PBS, fixed with 10%
Formalin, stained with crystal violet, and imaged under a IX70 microscope.

Scratch Assay
OS-33 cells were seeded from a 100 mm tissue culture plate into a 6-well Fisher
Scientific tissue culture plate and grown to complete confluency. A sterile p1000 pipette
tip was scratched slowly along the bottom each of the six wells to create a uniform
“scratch” or “wound” in the cells. Immediately after scratching, cells were rinsed five
times with PBS in order to remove cells which were displaced from the plate after
scratching. Full medium was added to three wells and full medium with 1 ng/mL
rapamycin was added to three wells. Then, the cells were imaged for initial wound size.
Directly after imaging, the plate was returned to incubation overnight. Photographs were
taken again at the initial wound sites and compared to the initial wound sizes in order to
measure overall migration and proliferation of OS-33 cells. NIH Image J (NIH, Bethesda,
MD, USA) was used to measure closure of the wound.
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Trans-well Migration Assay
Using an 8-µm Fisher Scientific pore-sized chamber system, a trans-well migration assay
was completed to test the overall ability of OS-33 cells to travel through a semi-porous
membrane towards a chemoattractant. The bottom chamber was filled with full medium
(MEM-alpha plus 10% Fetal Bovine Serum and 1% Penicillin-streptomycin) and 1
ng/mL rapamycin or 100% ethanol. Prior to setting up the migration assay, cells were
placed in serum-free medium overnight in order to make them more susceptible to travel
towards the chemoattractant and to prevent cellular proliferation. The serum-free cells
were treated with 1 ng/mL rapamycin or 100% ethanol and seeded at approximately
20,000 cells per well into the upper chamber above the membrane. Cells were returned to
incubation for 24 hours and then fixed in 10% formalin and stained with crystal violet
(Fisher Scientific, C581-25) the next day. The upper chamber was cleaned with PBS and
Q-tip before imaging with an IX70 microscope for qualitative results. After this, 33%
acetic acid was added to the stained cells, removing the stain from the cells. After
removing the crystal violet, 100 µL of the solution was moved into a new 96-well Falcon
plate. An optical density (OD) was taken at 570 nm on the Cytation3 and the results were
analyzed for quantification.

Trans-well Invasion Assay
The invasion assay was conducted exactly as described in the trans-well migration assay
previously, except there was a 0.2 mg/mL matrigel (Fisher Scientific, CB354248)
covering the membrane.
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Adipocyte Differentiation with Rapamycin Analysis
OS-33 was grown to 90% confluency in a 12-well Fisher Scientific plate and were treated
with adipocyte-inducing medium to induce cell differentiation into adipocytes in the OS
cell line. Medium was prepared by addition of 1 µL/mL of 125X IBMX, 1 µL/mL of 1
mM Dexamethasone, 1 µL/mL of 10 mg/mL Insulin, and 1 µL/mL of 1mM
Rosiglitazone to full MEM-alpha medium. This medium was used only for Day 0 of
treatment. In addition, 1 µL/mL of rapamycin was added to treated wells. In the medium
without rapamycin 1 µL/mL of 100% ethanol was added for control. Full MEM-alpha
medium without modification was used for control in untreated OS-33 cells. Cells were
seeded into a 12-well Fisher Scientific plate. On Day 0, cells were treated with the
prepared mediums. Cells were returned to incubation until day 4. Then, a medium change
was completed using full medium with 1 µL/mL of 10 mg/mL Insulin and 1 µL/mL of 1
mM Rosiglitazone. Medium change was completed every 3 days for 14 days, being
careful to never cross contaminate. At the end of the 14-day period, cells were fixed with
10 % formalin and stained with Oil Red-O and hematoxylin counter stain. Cells were
imaged for adipocyte differentiation under an IX70 microscope and counted using NIH
Image J.

Osteoblast Differentiation Analysis
Cells were grown to 90% confluency in a 12-well Fisher Scientific plate and treated with
osteoblast-inducing differentiation medium (control cells were grown in full MEM alpha
medium). This medium was prepared by adding 1 µL/mL of 14.5 mg/mL (50 mM,
1000X) ascorbic acid, 1 µL/mL of 100 µM Dexamethasone, and 10 µL/mL of 1 M BGP
9

(100X) to MEM Alpha Medium. Osteoblast-differentiation-inducing medium was added
to OS-33 cells and an L2 control cell line. The osteoblast-differentiation-inducing
medium and MEM Alpha Modification growth medium were changed every three days
for 14 days. On the 14th day, fixation with 10% formalin and Alizarin Red staining
(Sigma A5533, MW: 342.26, pH 4.2) was completed. Results were imaged under an
IX70 microscope. After initial results, 1 µL/mL of BMP-2 was added to the osteoblast
medium to further induce differentiation and C2C12 cells were used as a control cell line
as opposed to L2. C2C12 was used because of the capability for the cell line to
differentiate when BMP-2 was added to medium as described in previous literature [13].
BMP-2 was diluted with 5% DMSO.

Cell Proliferation with Rapamycin and Doxorubicin
OS-33 cells were rinsed with PBS and treated with 0.25% Trypsin-EDTA (1X) in a 10
mm tissue Fisher Scientific culture plate to remove cells from the plate. Cells were then
counted using trypan blue dye and a Countess cell counter. Several concentrations of
rapamycin were added by 1 µL/mL to full medium in order to produce 0, 3.125, 6.25,
12.25, 25, 50, and 100 ng/mL treatments. Cells were seeded using the prepared
rapamycin-treated full medium in a 96-well Fisher Scientific plate at 6,500 cells/well.
After 24 hours, a medium change was completed using the corresponding rapamycintreated full medium. At 45 hours, 10 µL of CCK-8 was added to each well. The CCK-8
treated cells were returned to incubation for 3 hours. At 48 hours, the concentration of
cells was counted with an OD on the Cytation3 instrument. Results were analyzed and
proliferation was compared between the differing rapamycin concentrations. These same
10

protocols were used for testing proliferation with doxorubicin and doxorubicin/rapamycin
combination therapy. Doxorubicin was diluted with 0.5 % DMSO and tested at 0, 1.5625,
3.125, 6.25, 12.5, and 50 µM. When testing combination therapy using doxorubicin and
rapamycin, a 1:2 doxorubicin to rapamycin constant-ratio drug treatment was
implemented in order to test the synergistic effects of the two drugs. Specifically,
concentrations of 0:0, 1.5625:3.125, 3.125:6.25, 6.25:12.5, 12.5:25, 25:50, and 50:100
µM:ng/mL were used. Corresponding amounts of ethanol and DMSO, respectively, were
used as controls.

Statistical Analysis
Microsoft Excel Sheets were used for statistical calculation and formation of graphs. A
two-tailed Student’s t-test was used to compare treatment groups in quantifications of
Western blot, proliferation assays, scratch assay, trans-well migration and invasion
assays. Statistical significance was determined at *P<0.05, **P<0.01, and ***P <0.001
for each test. NIH Image J was used for analyzing adipocyte differentiation and scratch
assays.
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CHAPTER THREE
Results
Characteristics of the OS-33 Cell Line
Karyotype Analysis

Figure 1: Karyotype analysis of the OS-33 cell line shows several chromosomal
abnormalities which are consistent with classical features from OS cancer cell lines.
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Karyotype analysis of the OS-33 cell line shows that 13 out of 20 chromosomes are
hyper-triploid aneuploidy. There were also well over 100 chromosomes and many broken
chromosomal fragments, called satellite DNA, which confirm OS-33 an abnormal and
human cancer cell line [14]. This complex karyotype is typical of a cancerous cell line
with a p53 mutation commonly found in OS [15].

Western Blot Analysis

A

B

Rapa (ng/mL)
0

0.1

1

1.2
1

10
pS6/S6 ratio

0.8
p-S6

0.6
0.4
0.2
0

S6

0
0.1
1
10
Rapamycin Concentrations
(ng/mL)

Figure 2: Western blot analysis of the pS6/S6 ratio indicates inhibition of the mTORC1
pathway with increasing levels of rapamycin treatment. A) Qualitative measurements of
Western blot analysis are displayed as imaged. B) The pS6/S6 ratio was analyzed and
quantified to show a decreasing pS6/S6 ratio with increasing rapamycin concentrations
(ng/mL).

In order to better understand how rapamycin inhibits the mTORC1 pathway, we
conducted Western blot analysis to look specifically at the phospho-S6 (pS6) to S6 ratio.
13

Since mTORC1 is a kinase cascade pathway, the upregulation of mTORC1 will increase
phosphorylation of a downstream target, S6 [16]. Therefore, increased levels of pS6 can
be found when activity of mTORC1 is increased. With increasing rapamycin treatment,
we see a smaller pS6 to S6 ratio. This indicates that the mTORC1 pathway is directly
inhibited with increased rapamycin treatment in OS-33.

Colony Formation Assay

A

0 ng/mL

B

0.1 ng/mL

C

1 ng/mL

Figure 3: Colony formation assay with 0, 0.1, and 1 ng/mL rapamycin treatment shows
inhibition of colony formation.

Over a 14-day period, OS-33 cells were monitored for colony forming activity and
imaged using a crystal violet stain. Results show that OS-33 has limited ability to form
colonies and colony formation is further inhibited by increasing rapamycin treatment. It
should be noted that these results are preliminary and further testing over a longer time
period has potential to result in colony formation.
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Scratch Assay

0 ng/mL

19 Hours

0 Hour

1 ng/mL

Figure 4: Scratch assay (wound healing assay) with 1 ng/mL rapamycin treatment shows
inhibition of wound closure with rapamycin treatment.

The general trend of migration and proliferation can be examined by a scratch assay,
where a decrease in the width of the “wound” or “scratch” in the cells overtime indicates
that OS-33 cells have proliferated or migrated. As shown in Figure 4, there was full
wound closure in the cells with 0 ng/mL rapamycin treatment. Treatment of OS-33 with 1
ng/mL rapamycin inhibits closure of the wound over time.
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Trans-well Migration Assay

1 ng/mL

B

120
100
80

**

Migration (%)

0 ng/mL

A

60
40
20
0
EtOH

Rapa
Treatment

Figure 5: The capacity of OS-33 to migrate through a semi-porous membrane in a transwell system was inhibited by rapamycin treatment. A) There is a visible decrease in the
number of cells which pass through to the chemoattractant in the bottom well as seen
through microscope imaging (10X) between ethanol treatment (0 ng/mL) and rapamycin
treatment (1 ng/mL). B) Quantitative analysis comparing ethanol (EtOH) and 1 ng/mL
rapamycin (Rapa) treatment shows decreased trans-well migration. Ethanol treatment
serves as a baseline for 100% migration which rapamycin treatment was compared to
and found significant (*P<0.05, **P<0.01, ***P <0.001).

Migration in a trans-well assay is measured by the number of cells which have passed
through the semi-porous membrane and are found on the bottom side of the cell culture
insert containing the chemo-attractant at the time of staining. A decreased number of cells
found in the chemo-attractant means that migration was inhibited. By comparing the
general images of the OS-33 cells treated with 0 ng/mL rapamycin (control) and 1 ng/mL
16

rapamycin and by quantifying the data with Cytation3, we can see that rapamycin
inhibited migration significantly. The inhibition of migration mimics the ability for OS
cells to travel through an extracellular matrix in vivo [17].

Trans-well Invasion Assay

B

140.0%
120.0%

0 ng/mL

Invasion

100.0%
80.0%

**

A

60.0%

1 ng/mL

40.0%
20.0%
0.0%

EtOH

Rapa
Treatment

Figure 6: The capacity of OS-33 to invade through a semi-porous membrane with a
matrigel in a trans-well system was inhibited by rapamycin treatment. A) There is a
visible decrease in the number of cells which pass through the matrigel to the
chemoattractant in the bottom well as seen through microscope imaging (10X) between
ethanol treatment (0 ng/mL) and rapamycin treatment (1 ng/mL). B) Quantitative
analysis comparing ethanol (EtOH) and 1 ng/mL rapamycin (Rapa) treatment shows
decreased trans-well invasion. Ethanol treatment serves as a baseline for invasion which
rapamycin treatment was compared to fractionally and found significant (*P<0.05,
**P<0.01, ***P <0.001).
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Similar to the migration assay, inhibition of invasion was qualitatively measured by
images and quantitatively measured OD with the Cytation3 instrument. With 1 ng/mL
rapamycin treatment, invasion was inhibited. This therefore indicates inhibition of the
mTORC1 pathway by rapamycin treatment.

Adipocyte Differentiation Analysis

Figure 7: Adipocyte differentiation assay of OS-33 cell line with 1 ng/mL rapamycin
treatment and adipocyte-inducing medium (AD).

Over a 14-day period, cell lines were treated with an adipocyte-inducing medium and 1
ng/mL rapamycin treatment or 100% ethanol. The purpose of this is to test the effects of
rapamycin treatment on mesenchymal stem cell differentiation. Staining with Oil Red-O
and Hematoxylin counter stain shows adipocyte formation. Lipid droplets appear in red.
OS-33 cell differentiation capacity was inhibited with rapamycin treatment.
18

Quantification shows significant results and inhibition. (*P<0.05, **P<0.01, ***P
<0.001).

Osteoblast Differentiation Analysis

L2

Treated

Untreated

OS-33

Figure 8: Osteoblast differentiation assay of OS-33 cell line with L2 control cell line
shows no differentiation with Alizarin red S staining in OS-33 cells.

Over 14 days, the two lines, OS-33 and L2 (control), were grown with and without
osteoblast-inducing medium. Medium changes were completed every three days and
afterwards cells were stained with Alizarin red S. While the L2 line showed high levels of
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mesenchymal stem cell differentiation as predicted, there was no differentiation in the
OS-33 cell line.

Osteoblast Differentiation with BMP-2 Analysis

C2C12

Treated

Untreated

OS-33

Figure 9: Osteoblast differentiation assay of the OS-33 and C2C12 cell lines with BMP-2
and stained with Alizarin red S shows osteoblast formation (in red).

After obtaining no differentiation with the osteoblast-inducing medium in the OS-33 cell
line, 1 µL/mL of the reagent BMP-2 was added to the medium in efforts to differentiate
stem cells into osteoblasts. C2C12 was used as a control cell line. After staining with
Alizarin red S, cells were imaged under an IX70 microscope and differentiation was
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shown in red. The OS-33 cells showed limited differentiation from mesenchymal stem
cells into osteoblasts.

Cell Proliferation with Rapamycin
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Figure 10: Cellular proliferation assay at 48 hours with OS-33 and increasing
rapamycin treatments using CCK-8 for quantification (*P<0.05, **P<0.01,
***P<0.001).

Results of the cell proliferation analysis for OS-33 with rapamycin treatment show a
general decrease in proliferation as the concentration of rapamycin treatment increases;
however, there showed to be no significant levels of inhibited proliferation. Best results
were obtained at 48 hours of treatment with media changes every 24 hours. The IC50
value was calculated to be 8.7 ng/mL.
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Cell Proliferation with Doxorubicin
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Figure 11: Cellular proliferation assay at 48 hours with OS-33 and increasing
doxorubicin treatments using CCK-8 for quantification (*P<0.05, **P<0.01, ***P
<0.001).

Results were obtained at 48 hours, with a media change at the 24-hour mark. As
expected, increasing doxorubicin treatment concentrations correlated with decreased
proliferation. A significant decrease in proliferation was found at 50 µM of doxorubicin
treatment. The IC50 value was calculated to be 9.5 µM.

22

Cell Proliferation Combination Therapy
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Figure 12: Cellular proliferation assay with OS-33 and increasing doxorubicin and
rapamycin constant-ratio combination drug therapy using CCK-8 for quantification
(*P<0.05, **P<0.01, ***P <0.001).

After obtaining significant results for both the rapamycin and doxorubicin cell
proliferation assays, a combination therapy technique was implemented in which a 1:2
ratio of doxorubicin to rapamycin treatment was tested. Results showed that rapamycin
and doxorubicin held significant synergistic effects in prohibiting the proliferation of the
OS-33 cell line.
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CHAPTER FOUR
Discussion
Conclusion and Future Directions
In this study, we discovered that the novel OS-33 cell line has capabilities to
proliferate, migrate, and differentiate; however, these capabilities can be limited by
inhibiting the mTORC1 pathway with use of rapamycin. A karyotype analysis of the OS33 cell line displayed severe abnormalities in the chromosomes and provided support that
this is a cancerous cell line originated from human osteosarcoma. Western blot analysis
quantified the inhibition of mTORC1 by displaying the decreased pS6/S6 ratio with
increasing rapamycin treatments on the OS-33 cell line, implicating a very high level
activity of mTORC1 signaling pathway in OS-33 cells. While the cell line showed
limited capabilities for colony formation, both with and without rapamycin treatment, it
did show decreasing ability to proliferate and migrate with rapamycin treatment in a
scratch assay. This led into further investigation of migration and invasion qualities of the
cell line. In both the migration and the invasion assays, the OS-33 cell line showed the
ability to move through wells towards the chemoattractant. Next, the ability to
differentiate was tested with both adipocyte-inducing medium and osteoblast-inducing
medium. The ability for OS-33 to differentiate into adipocytes was capable and was
inhibited with rapamycin treatment. This indicates stem cell potential to differentiate the
cancerous cells into normal, fat tissue. However, it should be noted that the formation of
lipid droplets was not normal of a classic adipocyte differentiation assay. In the future,
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use of adipocyte markers could give more clear results. There was no significant
differentiation of the OS-33 cell line into osteoblasts until the reagent BMP-2 was added.
Upon adding this reagent, there were significant levels of increased deposition of calcium
compounds, which were detected by Alizarin red S staining. In order to examine drug
sensitivity of OS-33, cellular proliferation assays were conducted using rapamycin,
doxorubicin, and a combination therapy treatment. While neither the rapamycin or
doxorubicin showed significant results alone (with the exception of 50 µM of
doxorubicin), when combined at 1:2 doxorubicin/rapamycin ratio, they were shown to
significantly inhibit proliferation by inhibition of the mTORC1 pathway.
The importance of this study as a whole shows how a novel osteosarcoma cell line
is directly affected by targeting the mTORC1 pathway. Using rapamycin, a known
mTORC1 inhibitor, inhibited the migrating, invading, and differentiating capabilities of
OS-33. Furthermore, when doxorubicin is added to the rapamycin treated cells there is a
synergistic effect of combining two inhibitors of proliferative capabilities. The data
confirms that the cancerous OS-33 cell line is dependent on the mTORC1 pathway,
which is consistent with previous studies highlighting the importance of using the
mTORC1 signaling pathway as a therapeutic marker in cancerous cell lines [18].
Together, our study, which uses a novel OS cell line, will help others understand the
importance of the mTORC1 signaling pathway and provide a new tool to study OS
biology in general, as well as to find potential drugs targeting OS cells.
As with every study, error and alternative explanations should always be
considered as a possibility. This study was limited to a 3-month period of work. The
mTORC1 inhibition by rapamycin and doxorubicin was only studied on the OS-33
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osteosarcoma cell line in this study. Experiments are also limited to the accuracy of cell
Countess instrument and the Cytation3. It should also be noted that imaging could be
unintentionally biased towards the results of experiment with limited numbers of
experiments. Experiments such as the colony formation assay could show differing
results over a longer time-period. Thus, those data presented in this thesis are very
preliminary and need to be further studied.
The results provided in this paper could provide preliminary pre-clinical evidence
for future clinical trials using rapamycin in osteosarcoma patients in combination with
other drugs. This holds the potential to change the options for future patient treatment.
Specifically, we hope that treatment methods can target metastasis and prevent spreading
or growth of tumors.
Using OS-33 cells, we plan to further test the effects of combination therapy using
doxorubicin and rapamycin treatments. We hope to implement combination therapy
treatments into other experiments to see how it would affect results from Western blot
analysis, trans-well migration and invasion, scratch assays, and colony formation assays.
These experiments would give a greater understanding of the synergistic effects of the
two drug treatments. Results of combination therapy could provide pre-clinical evidence
for future clinical trials, which could change the options for human patient treatment. We
will also implement nude-mice xenografts and treatment to test inhibition of the
mTORC1 pathway and cancer proliferation in vivo. By using immune-deficient mouse
models, future studies may implement the OS-33 cell line and test the effects of
combination therapy. This warrants with our continuing use of the OS-33 cell line.
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The results obtained in this study played a major role in defining the novel OS-33
osteosarcoma cell line. Through various experiments, we explored the role of mTORC1
signaling pathway plays in osteosarcoma proliferation and migration. This will help us to
explore new possible combination therapy treatments. The intention of these treatments is
to prevent metastasis, which is more resistant to conventional cancer therapies and is
more difficult to remove than a tumor [19]. By better understanding osteosarcoma as a
cancer model, metastasis of the cancer, and the mTORC1 pathway, we are unlocking
improved possible treatment methods for patients.
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